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Abstract
Dopa-Responsive Dystonia (DRD) is a rare hereditary 
condition of childhood-onset dystonia which responds 
dramatically to treatment with levodopa. It was first described 
in 1971 as a “hereditary progressive basal ganglia disease with 
marked diurnal fluctuation”. We describe a novel association 
between DRD and hyperprolactinaemia occurring in two sisters 
at the onset of puberty.
Introduction
We report on two sisters, diagnosed with dopa-responsive 
dystonia (DRD) at the ages of 8 and 11 years, who later developed 
hyperprolactinaemia. 
Case report
These sisters had been seen for many years by various 
paediatricians for delayed developmental landmarks and 
hypotonia.  
By the age of 9 months, the elder sister, who had a normal 
birth history, had been repetitively admitted to hospital due 
to severe recurrent upper respiratory tract infections. The 
girl was noted to have delay in gross motor development with 
hypotonia, poor head control and a weak hand grip. She could 
not sit upright unsupported. No abnormal movements were 
noted. She attained unsupported sitting at 18 months. An EEG 
and EMG at the time were normal.
At the age of 1 year, she could only tolerate liquid foods 
and vomited daily. On examination she had occasional left 
and upward conjugate deviation of both eyes with slight 
nystagmus; direct and consensual light reflexes were normal. 
She had slow tongue movements with dysarthria and dribbling 
of saliva. Muscle power was graded 3/5 in all 4 limbs. A coarse 
intentional tremor and clasp-knife rigidity were present in both 
upper limbs; hypotonia more evident in the lower limbs. Brisk 
reflexes were present; plantar reflexes normal. High arched feet 
with prominent calcanei were also noted. Co-ordination was 
unaffected but gait was ataxic. A CT scan of the brain revealed 
small frontal atrophic changes. Hypotonic cerebral palsy was 
the working diagnosis at this time. 
At the age of 2 she was continent of both urine and faeces, 
was still on liquid foods and vomited regularly. Her vocabulary 
had broadened up to 20 words. Her vision and hearing remained 
unaffected.
She attended speech therapy for her dysarthria with minimal 
improvement. The palmer grasp was still present, but she was 
able to co-ordinate her finger movements. She could build a 
tower of 10 blocks. 
By age 3, her speech had improved and she could 
communicate in short phrases. Dribbling of saliva was still 
present. Proper chewing of foods had not yet been developed and 
she was still vomiting daily, often in copious amounts. Weight 
gain was hence insignificant. 
At age 5, diurnal fluctuation of fatigue was evident. A year 
later hypotonia had not improved and pyramidal signs were 
present. She had an ataxic gait, with no swinging movements of 
the upper limbs. There was also mild cognitive impairment. 
Her sister, who was 2 years younger, also presented at a 
young age with similar symptoms. At birth she suffered an 
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oculogyric crisis and during infancy, she had gross motor delay 
and recurrent upper respiratory infections. She was hypotonic 
with subsequent development of generalised spasticity and 
prominent truncal ataxia. Physical examination also revealed 
bilateral flat feet with genu varum and pes cavus with calcaneo 
valgus. She was continent of both urine and faeces. At the time, 
the working diagnosis was spastic quadraparesis with global 
developmental delay and immature speech.     
At this stage, the possibility of dopa-responsive dystonia was 
considered in both girls. When the elder sister was 11 years of 
age, a small dose of co-careldopa (levodopa and carbidopa) was 
prescribed to both sisters as a diagnostic and therapeutic trial. 
Her younger sister showed excellent response to the treatment. 
However, the elder sister’s improvement was more gradual 
and to a lesser degree. Their handwriting and waddling gait 
improved. They fell less frequently and were less lethargic in 
the evenings. Mild dystonic positioning of the left hand present 
in both sisters remained but this also gradually improved. They 
attended school with facilitation. Interestingly, both sisters 
remained hypotonic even after treatment. They eventually 
developed marked scoliosis.  
The elder sister’s sexual development started at the age of 
9 years and menarche occurred at 16 years. 
No further menses followed except for occasional spotting 
of altered blood. She was reviewed and hyperprolactinaemia 
was identified with a prolactin level of 8275mU/L (Normal 
serum level 40-530mU/L). At this point she was referred to an 
endocrine clinic for further evaluation. Physical examination 
revealed acne, galactorrhoea, mild scoliosis, hypotonia with 
mild dystonia in all 4 limbs and a waddling gait. Tunnel vision 
was noted on ophthalmic assessment. An MRI scan of the brain 
and pituitary gland identified no intracranial pathology. She was 
started on bromocriptine 1.25mg daily. After starting treatment, 
she developed regular menses, no further galactorrhoea was 
reported but hirsuitism was still present. Her gait improved 
further but lower limbs still showed a waddling gait. Prolactin 
levels returned to normal. The MRI scan, which was repeated 
a year later, confirmed no identifiable pathology. At the 
time, the patient was stable on co-careldopa 110mg daily and 
bromocriptine 2.5mg daily. 
At the age of 13 years the younger sister was also screened 
for hyperprolactinaemia, which was initially normal but started 
to rise on follow up visits. Her prolactin levels had increased 
to 1119mU/L. Menarche had occurred at the age of 12. Her 
presenting complaint was hirsuitism. There were no visual field 
defects. An MRI showed a small microadenoma. She was initially 
treated with bromocriptine, but some months later changed to 
cabergoline. Her prolactin levels normalised.
Discussion
Dopa-Responsive Dystonia (DRD) is a hereditary condition 
characterised by childhood-onset dystonia with diurnal 
fluctuation of symptoms, being worse towards the evening. This 
condition responds dramatically to treatment with levodopa. It 
was first described in 1971 by Segawa et al, who described the 
condition as “hereditary progressive basal ganglia disease with 
marked diurnal fluctuation.”1 
There are 2 types of DRD, autosomal-dominant and 
recessive, the former being the commonest form.
DRD is characterised by dopamine deficiency in the 
striatum.2 There is decreased dopamine activity at the 
nigrostriatal terminals in patients suffering from DRD.2 This is 
not due to a morphological disorder, as in Parkinson’s disease, 
but is related to a functional disorder of the nigrostriatal 
dopamine (DA) neuron, with the striatum being free of a 
primary lesion.3 
Tyrosine hydroxylase (TH) acts on tyrosine to produce 
dopamine. TH is a rate limiting enzyme in the synthesis of 
dopamine.2 Tetrahydropterin (BH4), its cofactor, is synthesised 
from GTP in a 3-enzyme pathway, which includes GTP 
cyclohydrolase I (GCH).4Neurohistochemical examinations 
show low BH4 concentrations resulting in decreased TH activity 
and its protein in the striatum or at the terminal of the nigro-
striatal neuron.3 There are normal levels of TH protein and 
its activity in the substantia nigra.3 Low BH4 levels could be 
congenital but is commonly an indirect result of mutations in 
the GCH-I gene.3 This gene codes for Guanosine Triphosphate 
(GTP) cyclohydrolase I enzyme. Various mutations in the GCH-I 
gene have been identified.4 Furukawa observed that the locus of 
mutations is different between different families but identical 
within a family.5 GCH activity in patients with DRD would be 
low, resulting in a slow production of BH4, which does not meet 
up to its daily consumption.6 
However, physical signs and symptoms present in DRD 
patients are attributed to dopamine deficiency in the striatum 
rather than deficiency of BH4.6 Symptoms are worse towards 
the evening due to depletion of the BH4 pool.6 
Reduced neopterin levels distinguish DRD from degenerative 
nigro-striatal dopamine deficiency disorders.7 Neopterin levels 
are reduced in the striatum, putamen and even in the CSF of 
patients with DRD.4 Neopterin indirectly reflects the activity of 
GCH in the brain as it is a metabolite of an intermediate in the 
biosynthesis of BH4.6   
Signs and symptoms develop in early childhood. The main 
characteristic is gait disturbance with postural dystonia. The 
patient tends to walk in an equines posture. As the patient 
gets older and if no treatment is given, the dystonia spreads 
to affect the trunk and all four limbs. Muscle tone is increased 
and tendon reflexes tend to be exaggerated. The progression of 
dystonia tends to subside by the forth decade.3 Postural tremor 
develops in the third decade. Resting tremor is not present as 
in patients with Parkinson’s disease. There are no mental or 
psychological abnormalities. Autonomic nervous symptoms 
are not present.3 
The clinical course of DRD is dependant on the age of onset. 
For example, those patients whose symptoms start in adulthood 
tend to develop a hand tremor without dystonia and diurnal 
variation.3 
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DRD is usually diagnosed by the administration of 
small doses of levodopa resulting in marked symptomatic 
improvement, with relatively few side-effects related to 
levodopa treatment and no long-term complications, such as 
those seen in Parkinson’s disease.1 There are laboratory tests 
available but are not routinely performed. Biochemical tests 
include the measurement of neopterin and biopterin levels 
and neurotransmitter metabolites, HVA and 5HIAA, in the 
cerebrospinal fluid and the phenylalanine loading tests. Imaging 
studies are performed but are not conclusive.4 
Treatment mainly involves the administration of a 
combination of levodopa and carbidopa. The two girls 
mentioned in the above report were started on this treatment 
with good results. A randomised controlled study, involving 
patients with Parkinson’s disease, carried out by Montastruc et 
al. shows that treatment with high doses of bromocriptine for the 
first 3 years followed by the administration of levodopa delays 
the onset of motor complications. It gives better symptomatic 
relief than with levodopa alone.8 
The cause for the co-existence of hyperprolactinaemia 
identified in both sisters with DRD in the above case report still 
has to be established. A study carried out on patients suffering 
from metastatic carcinoma of the prostate identified paradoxical 
stimulation of prolactin secretion on administration of levodopa 
to these patients.9 There could be unidentified pathways 
susceptible to dopamine deficiency which, on administration 
of levodopa, affects the neuroendocrine regulation of prolactin 
release. Dopamine is a prolactin-inhibiting factor.10 In a study it 
was noted that hyperprolactinaemia was present in patients with 
autosomal recessive BH4 deficiency and with the recessively 
inherited severe form of TH deficiency.10 Prolactin levels are 
normal in the autosomal dominant GTPCH-deficient DRD. 
The hypothalamic dopamine loss in these patients could not be 
sufficient enough to cause a rise in the serum prolactin.10 
DRD and hyperprolactinaemia in both sisters could be 
unrelated but may be due to a genetic defect giving rise to the co-
existence of both conditions. The fact that both sisters developed 
hyperprolactinaemia shortly after the onset of menarche makes 
a genetic link more likely. 
References
1. Mink JW. Dopa-Responsive Dystonia in children. Current 
Treatment Options in Neurology 2003,5:279-82. 
2. Nikhar NK. Dopa-Responsive Dystonia. Emedicine 2005. 
 http://www.emedicine.com/neuro/topic618.htm.
3. Segawa M, Nomura Y, Nishiyama N. Autosomal dominant 
Guanosine Triphosphate cyclohydrolase I deficiency (Segawa 
disease). Ann Neurol 2003;54 (suppl 6):S32-45.
4. Blau N, Bonafe L, Thony B. Tetrahydrobiopterin deficiencies 
without hyperphenylalaninaemia: diagnosis and genetics of dopa-
responsive dystonia and siapterin reductase deficiency. Molecular 
Genetics and Metabolism 2001;74,172-85.
5. Furukawa Y. Genetics and biochemistry of dopa-responsive 
dystonia: significance of striatal tyrosine hydroxylase protein loss. 
Adv Neurol 2003;91:410.
6. Ichinose H, Ohye T, Matsuda Y, Hori T, Blau N, Burlina A, et 
al. Molecular mechanisms of hereditary progressive dystonia 
with marked diurnal fluctuation, Segawa’s disease. Brain and 
Development 2000;22:S107-10.
7. Furukawa Y, Nygaard TG, Gutlich M, Rajput AH, Pifl C, DiStefano 
L, et al. Striatal biopterin and tyrosine hydroxylase protein 
reduction in dopa-responsive dystonia. Neurology 1999;53:1032. 
8. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised 
controlled study comparing bromocriptine to which levodopa 
was later added, with levodopa alone in previously untreated 
patients with Parkinson’s disease; a five year follow up. Journal of 
Neurology, Neurosurgery and Psychiatry 1994;57:1034-8.
9. Lissoni P, Mandala M, Rovelli F, Casu M, Rocco F, Tancini G, et 
al. Paradoxical Stimulation of Prolactin Secretion by l-dopa in 
metastatic prostate cancer and its possible role in prostate-cancer-
related hyperprolactinaemia. Eur Urol 2000;37:569-72.
10. Furukawa Y, Guttman M, Wong H, Farrell SA, Furtado S, Kish 
SJ, et al. Serum prolactin in symptomatic and asymptomatic 
dopa-responsive dystonia due to a GCH1 mutation. Neurology 
2003;61:269-70.
